Table 3. Cox proportional hazards analyses for progression-free survival and overall survival.
| Variables | PFS | OS | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Univariate | |||||
| Age, y (<60 vs. ≥60) | 0.809 (0.488–1.341) | 0.411 | 0.948 (0.510–1.764) | 0.867 | |
| Gender (male vs. female) | 1.417 (0.816–2.462) | 0.216 | 0.896 (0.438–1.833) | 0.763 | |
| Pathological types (adenocarcinoma vs. squamous vs. others) | 0.604 (0.366–0.996) | 0.048* | 1.160 (0.658–2.043) | 0.608 | |
| Tumor differentiation (poor vs. moderate) | 0.513 (0.306–0.861) | 0.012* | 0.638 (0.341–1.194) | 0.160 | |
| TNM Stage (I-II vs. III-IV) | 2.792 (1.654–4.711) | 0.000* | 3.504 (1.880–6.530) | 0.000* | |
| Smoking history (never vs. smoker) | 0.756 (0.446–1.279) | 0.297 | 1.367 (0.683–2.738) | 0.377 | |
| MCT4 expression (low vs. high) | 1.727 (1.041–2.864) | 0.034* | 1.962 (1.048–3.674) | 0.035* | |
| MCT1 expression (low vs. high) | 0.677 (0.321–1.428) | 0.305 | 1.248 (0.574–2.710) | 0.576 | |
| Multivariate | |||||
| Pathological types (adenocarcinoma vs. squamous vs. others) | 0.788 (0.472–1.317) | 0.363 | 1.609 (0.899–2.877 | 0.109 | |
| Tumor differentiation (poor vs. moderate) | 0.555 (0.322–0.957) | 0.034* | 0.752 (0.394–1.437) | 0.389 | |
| TNM Stage (I-II vs. III-IV) | 2.492 (1.442–4.307) | 0.001* | 3.725 (1.957–7088) | 0.000* | |
| MCT-4 expression (low vs. high) | 1.888 (1.114–3.199) | 0.018* | 2.421 (1.271–4.610) | 0.007* | |
*P<0.05.